Xiamen Kingdomway Group Valuation

Q: What is the Fair Price of 002626 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002626 (CN¥15.74) is trading above our estimate of [[fair value]] (CN¥3.97)

Is 002626 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002626 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002626 (CN¥15.74) is trading above our estimate of fair value (CN¥3.97)

Significantly Below Fair Value: 002626 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002626?

Key metric: As 002626 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002626. This is calculated by dividing 002626's market cap by their current earnings.
What is 002626's PE Ratio?
PE Ratio	37.8x
Earnings	CN¥253.95m
Market Cap	CN¥9.60b

002626 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.1x
Enterprise Value/EBITDA	19.3x
PEG Ratio	1x

Price to Earnings Ratio vs Peers

How does 002626's PE Ratio compare to its peers?

The above table shows the PE ratio for 002626 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	51.9x
688658 Youcare Pharmaceutical Group	40.3x	26.2%	CN¥9.0b
600812 North China Pharmaceutical Company.Ltd	119.3x	n/a	CN¥9.5b
600422 KPC PharmaceuticalsInc	24.8x	28.1%	CN¥11.0b
600993 Mayinglong Pharmaceutical Group	23.1x	18.9%	CN¥11.0b
002626 Xiamen Kingdomway Group	37.8x	37.9%	CN¥9.6b

Price-To-Earnings vs Peers: 002626 is good value based on its Price-To-Earnings Ratio (37.8x) compared to the peer average (51x).

Price to Earnings Ratio vs Industry

How does 002626's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 002626 is expensive based on its Price-To-Earnings Ratio (37.8x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 002626's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002626 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	37.8x
Fair PE Ratio	34.6x

Price-To-Earnings vs Fair Ratio: 002626 is expensive based on its Price-To-Earnings Ratio (37.8x) compared to the estimated Fair Price-To-Earnings Ratio (34.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥49.3b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

3.7%

7.9%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

-1.8%

12.8%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

-3.1%

-24.5%